Edward Roddy e.roddy@keele.ac.uk
Should all people starting urate-lowering therapy for gout receive anti-inflammatory prophylaxis?
Roddy, Edward; Prior, James A.; Mallen, Christian D.
Authors
Dr James Prior j.a.prior@keele.ac.uk
Christian Mallen c.d.mallen@keele.ac.uk
Abstract
Co-prescription of anti-inflammatory prophylaxis with colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), or corticosteroids when initiating urate-lowering therapy (ULT) for gout is recommended in clinical guidelines to prevent ULT-induced flares and optimise adherence to ULT. Colchicine prophylaxis is highly clinically and cost-effective and there has been great interest recently in its cardioprotective effects. However, one in four people initiating ULT without prophylaxis in randomised trials do not have a gout flare within six months of initiation, raising the question of whether all people initiating ULT for gout should receive prophylaxis. Uptake of prophylaxis varies and appears to be common in secondary care settings but less commonly used in primary care, where most people with gout are managed and gout may be less severe. Recent clinical guidelines have highlighted that the patient’s perspective is important and that the pros and cons of prophylaxis should be discussed with people with gout initiating ULT. Uptake of prophylaxis seems likely to be influenced by perception of an individual’s risk of ULT-induced flares, as well as concerns about adverse events, polypharmacy, drug interactions, and cost. We advocate a personalised approach between people with gout and clinicians to reach shared treatment decisions when considering co-prescription of prophylaxis when initiating ULT, empowering people with gout to make decisions about their care
Citation
Roddy, E., Prior, J. A., & Mallen, C. D. (2024). Should all people starting urate-lowering therapy for gout receive anti-inflammatory prophylaxis?. Exploration of Musculoskeletal Diseases, 2, 521-528. https://doi.org/10.37349/emd.2024.00076
Journal Article Type | Commentary |
---|---|
Acceptance Date | Oct 29, 2024 |
Online Publication Date | Nov 15, 2024 |
Publication Date | Nov 15, 2024 |
Deposit Date | Nov 18, 2024 |
Journal | Exploration of Musculoskeletal Diseases |
Electronic ISSN | 2836-6468 |
Publisher | Open Exploration |
Peer Reviewed | Peer Reviewed |
Volume | 2 |
Pages | 521-528 |
DOI | https://doi.org/10.37349/emd.2024.00076 |
Keywords | Gout, urate-lowering therapy, colchicine |
Public URL | https://keele-repository.worktribe.com/output/977979 |
Publisher URL | https://www.explorationpub.com/Journals/emd/Article/100776 |
You might also like
Barriers and facilitators in diagnosing axial spondyloarthritis: a qualitative study
(2024)
Journal Article
Diagnostic delay in adult inflammatory bowel disease: A systematic review
(2023)
Journal Article
Diagnostic delay in axial spondyloarthritis: a systematic review
(2022)
Journal Article
Reply
(2021)
Journal Article
Downloadable Citations
About Keele Repository
Administrator e-mail: research.openaccess@keele.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search